 | • レポートコード：MRC2-11QY06749 • 出版社/出版日：QYResearch / 2020年11月20日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、114ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療、製薬 |
| Single User | ￥585,000 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥877,500 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,170,000 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料は遺伝性疾患薬のグローバル市場について調査・分析したレポートです。種類別（嚢胞性線維症（CF）、デュシェンヌ型筋ジストロフィー（DMD）、リソソーム蓄積症（LSD）、発作性夜間ヘモグロビン尿症（PNH））市場規模、用途別（クリニック、病院）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別遺伝性疾患薬の競争状況、市場シェア ・世界の遺伝性疾患薬市場：種類別市場規模 2015年-2020年（嚢胞性線維症（CF）、デュシェンヌ型筋ジストロフィー（DMD）、リソソーム蓄積症（LSD）、発作性夜間ヘモグロビン尿症（PNH）） ・世界の遺伝性疾患薬市場：種類別市場規模予測 2021年-2026年（嚢胞性線維症（CF）、デュシェンヌ型筋ジストロフィー（DMD）、リソソーム蓄積症（LSD）、発作性夜間ヘモグロビン尿症（PNH）） ・世界の遺伝性疾患薬市場：用途別市場規模 2015年-2020年（クリニック、病院） ・世界の遺伝性疾患薬市場：用途別市場規模予測 2021年-2026年（クリニック、病院） ・北米の遺伝性疾患薬市場分析：米国、カナダ ・ヨーロッパの遺伝性疾患薬市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの遺伝性疾患薬市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の遺伝性疾患薬市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの遺伝性疾患薬市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：Sanofi、Vertex、Takeda、Amgen、GW Pharmaceuticals、Pfizer、BioMarin、Sarepta ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
Market Analysis and Insights: Global Genetic Disorders Drug Market
The global Genetic Disorders Drug market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.
Global Genetic Disorders Drug Scope and Market Size
Genetic Disorders Drug market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Genetic Disorders Drug market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.
Segment by Type, the Genetic Disorders Drug market is segmented into
Cystic Fibrosis (CF)
Duchenne Muscular Dystrophy (DMD)
Lysosomal Storage Disease (LSD)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Segment by Application, the Genetic Disorders Drug market is segmented into
Clinic
Hospital
Regional and Country-level Analysis
The Genetic Disorders Drug market is analysed and market size information is provided by regions (countries).
The key regions covered in the Genetic Disorders Drug market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Genetic Disorders Drug Market Share Analysis
Genetic Disorders Drug market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Genetic Disorders Drug business, the date to enter into the Genetic Disorders Drug market, Genetic Disorders Drug product introduction, recent developments, etc.
The major vendors covered:
Sanofi
Vertex
Takeda
Amgen
GW Pharmaceuticals
Pfizer
BioMarin
Sarepta
1 Study Coverage
1.1 Genetic Disorders Drug Product Introduction
1.2 Market Segments
1.3 Key Genetic Disorders Drug Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Genetic Disorders Drug Market Size Growth Rate by Type
1.4.2 Cystic Fibrosis (CF)
1.4.3 Duchenne Muscular Dystrophy (DMD)
1.4.4 Lysosomal Storage Disease (LSD)
1.4.5 Paroxysmal Nocturnal Hemoglobinuria (PNH)
1.5 Market by Application
1.5.1 Global Genetic Disorders Drug Market Size Growth Rate by Application
1.5.2 Clinic
1.5.3 Hospital
1.6 Study Objectives
1.7 Years Considered
2 Executive Summary
2.1 Global Genetic Disorders Drug Market Size, Estimates and Forecasts
2.1.1 Global Genetic Disorders Drug Revenue 2015-2026
2.1.2 Global Genetic Disorders Drug Sales 2015-2026
2.2 Global Genetic Disorders Drug, Market Size by Producing Regions: 2015 VS 2020 VS 2026
2.2.1 Global Genetic Disorders Drug Retrospective Market Scenario in Sales by Region: 2015-2020
2.2.2 Global Genetic Disorders Drug Retrospective Market Scenario in Revenue by Region: 2015-2020
3 Global Genetic Disorders Drug Competitor Landscape by Players
3.1 Genetic Disorders Drug Sales by Manufacturers
3.1.1 Genetic Disorders Drug Sales by Manufacturers (2015-2020)
3.1.2 Genetic Disorders Drug Sales Market Share by Manufacturers (2015-2020)
3.2 Genetic Disorders Drug Revenue by Manufacturers
3.2.1 Genetic Disorders Drug Revenue by Manufacturers (2015-2020)
3.2.2 Genetic Disorders Drug Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Genetic Disorders Drug Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by Genetic Disorders Drug Revenue in 2019
3.2.5 Global Genetic Disorders Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Genetic Disorders Drug Price by Manufacturers
3.4 Genetic Disorders Drug Manufacturing Base Distribution, Product Types
3.4.1 Genetic Disorders Drug Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Genetic Disorders Drug Product Type
3.4.3 Date of International Manufacturers Enter into Genetic Disorders Drug Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Genetic Disorders Drug Market Size by Type (2015-2020)
4.1.1 Global Genetic Disorders Drug Sales by Type (2015-2020)
4.1.2 Global Genetic Disorders Drug Revenue by Type (2015-2020)
4.1.3 Genetic Disorders Drug Average Selling Price (ASP) by Type (2015-2026)
4.2 Global Genetic Disorders Drug Market Size Forecast by Type (2021-2026)
4.2.1 Global Genetic Disorders Drug Sales Forecast by Type (2021-2026)
4.2.2 Global Genetic Disorders Drug Revenue Forecast by Type (2021-2026)
4.2.3 Genetic Disorders Drug Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global Genetic Disorders Drug Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End
5 Market Size by Application (2015-2026)
5.1 Global Genetic Disorders Drug Market Size by Application (2015-2020)
5.1.1 Global Genetic Disorders Drug Sales by Application (2015-2020)
5.1.2 Global Genetic Disorders Drug Revenue by Application (2015-2020)
5.1.3 Genetic Disorders Drug Price by Application (2015-2020)
5.2 Genetic Disorders Drug Market Size Forecast by Application (2021-2026)
5.2.1 Global Genetic Disorders Drug Sales Forecast by Application (2021-2026)
5.2.2 Global Genetic Disorders Drug Revenue Forecast by Application (2021-2026)
5.2.3 Global Genetic Disorders Drug Price Forecast by Application (2021-2026)
6 North America
6.1 North America Genetic Disorders Drug by Country
6.1.1 North America Genetic Disorders Drug Sales by Country
6.1.2 North America Genetic Disorders Drug Revenue by Country
6.1.3 U.S.
6.1.4 Canada
6.2 North America Genetic Disorders Drug Market Facts & Figures by Type
6.3 North America Genetic Disorders Drug Market Facts & Figures by Application
7 Europe
7.1 Europe Genetic Disorders Drug by Country
7.1.1 Europe Genetic Disorders Drug Sales by Country
7.1.2 Europe Genetic Disorders Drug Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 U.K.
7.1.6 Italy
7.1.7 Russia
7.2 Europe Genetic Disorders Drug Market Facts & Figures by Type
7.3 Europe Genetic Disorders Drug Market Facts & Figures by Application
8 Asia Pacific
8.1 Asia Pacific Genetic Disorders Drug by Region
8.1.1 Asia Pacific Genetic Disorders Drug Sales by Region
8.1.2 Asia Pacific Genetic Disorders Drug Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Taiwan
8.1.9 Indonesia
8.1.10 Thailand
8.1.11 Malaysia
8.1.12 Philippines
8.1.13 Vietnam
8.2 Asia Pacific Genetic Disorders Drug Market Facts & Figures by Type
8.3 Asia Pacific Genetic Disorders Drug Market Facts & Figures by Application
9 Latin America
9.1 Latin America Genetic Disorders Drug by Country
9.1.1 Latin America Genetic Disorders Drug Sales by Country
9.1.2 Latin America Genetic Disorders Drug Revenue by Country
9.1.3 Mexico
9.1.4 Brazil
9.1.5 Argentina
9.2 Central & South America Genetic Disorders Drug Market Facts & Figures by Type
9.3 Central & South America Genetic Disorders Drug Market Facts & Figures by Application
10 Middle East and Africa
10.1 Middle East and Africa Genetic Disorders Drug by Country
10.1.1 Middle East and Africa Genetic Disorders Drug Sales by Country
10.1.2 Middle East and Africa Genetic Disorders Drug Revenue by Country
10.1.3 Turkey
10.1.4 Saudi Arabia
10.1.5 U.A.E
10.2 Middle East and Africa Genetic Disorders Drug Market Facts & Figures by Type
10.3 Middle East and Africa Genetic Disorders Drug Market Facts & Figures by Application
11 Company Profiles
11.1 Sanofi
11.1.1 Sanofi Corporation Information
11.1.2 Sanofi Description and Business Overview
11.1.3 Sanofi Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Sanofi Genetic Disorders Drug Products Offered
11.1.5 Sanofi Related Developments
11.2 Vertex
11.2.1 Vertex Corporation Information
11.2.2 Vertex Description and Business Overview
11.2.3 Vertex Sales, Revenue and Gross Margin (2015-2020)
11.2.4 Vertex Genetic Disorders Drug Products Offered
11.2.5 Vertex Related Developments
11.3 Takeda
11.3.1 Takeda Corporation Information
11.3.2 Takeda Description and Business Overview
11.3.3 Takeda Sales, Revenue and Gross Margin (2015-2020)
11.3.4 Takeda Genetic Disorders Drug Products Offered
11.3.5 Takeda Related Developments
11.4 Amgen
11.4.1 Amgen Corporation Information
11.4.2 Amgen Description and Business Overview
11.4.3 Amgen Sales, Revenue and Gross Margin (2015-2020)
11.4.4 Amgen Genetic Disorders Drug Products Offered
11.4.5 Amgen Related Developments
11.5 GW Pharmaceuticals
11.5.1 GW Pharmaceuticals Corporation Information
11.5.2 GW Pharmaceuticals Description and Business Overview
11.5.3 GW Pharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
11.5.4 GW Pharmaceuticals Genetic Disorders Drug Products Offered
11.5.5 GW Pharmaceuticals Related Developments
11.6 Pfizer
11.6.1 Pfizer Corporation Information
11.6.2 Pfizer Description and Business Overview
11.6.3 Pfizer Sales, Revenue and Gross Margin (2015-2020)
11.6.4 Pfizer Genetic Disorders Drug Products Offered
11.6.5 Pfizer Related Developments
11.7 BioMarin
11.7.1 BioMarin Corporation Information
11.7.2 BioMarin Description and Business Overview
11.7.3 BioMarin Sales, Revenue and Gross Margin (2015-2020)
11.7.4 BioMarin Genetic Disorders Drug Products Offered
11.7.5 BioMarin Related Developments
11.8 Sarepta
11.8.1 Sarepta Corporation Information
11.8.2 Sarepta Description and Business Overview
11.8.3 Sarepta Sales, Revenue and Gross Margin (2015-2020)
11.8.4 Sarepta Genetic Disorders Drug Products Offered
11.8.5 Sarepta Related Developments
11.1 Sanofi
11.1.1 Sanofi Corporation Information
11.1.2 Sanofi Description and Business Overview
11.1.3 Sanofi Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Sanofi Genetic Disorders Drug Products Offered
11.1.5 Sanofi Related Developments
12 Future Forecast by Regions (Countries) (2021-2026)
12.1 Genetic Disorders Drug Market Estimates and Projections by Region
12.1.1 Global Genetic Disorders Drug Sales Forecast by Regions 2021-2026
12.1.2 Global Genetic Disorders Drug Revenue Forecast by Regions 2021-2026
12.2 North America Genetic Disorders Drug Market Size Forecast (2021-2026)
12.2.1 North America: Genetic Disorders Drug Sales Forecast (2021-2026)
12.2.2 North America: Genetic Disorders Drug Revenue Forecast (2021-2026)
12.2.3 North America: Genetic Disorders Drug Market Size Forecast by Country (2021-2026)
12.3 Europe Genetic Disorders Drug Market Size Forecast (2021-2026)
12.3.1 Europe: Genetic Disorders Drug Sales Forecast (2021-2026)
12.3.2 Europe: Genetic Disorders Drug Revenue Forecast (2021-2026)
12.3.3 Europe: Genetic Disorders Drug Market Size Forecast by Country (2021-2026)
12.4 Asia Pacific Genetic Disorders Drug Market Size Forecast (2021-2026)
12.4.1 Asia Pacific: Genetic Disorders Drug Sales Forecast (2021-2026)
12.4.2 Asia Pacific: Genetic Disorders Drug Revenue Forecast (2021-2026)
12.4.3 Asia Pacific: Genetic Disorders Drug Market Size Forecast by Region (2021-2026)
12.5 Latin America Genetic Disorders Drug Market Size Forecast (2021-2026)
12.5.1 Latin America: Genetic Disorders Drug Sales Forecast (2021-2026)
12.5.2 Latin America: Genetic Disorders Drug Revenue Forecast (2021-2026)
12.5.3 Latin America: Genetic Disorders Drug Market Size Forecast by Country (2021-2026)
12.6 Middle East and Africa Genetic Disorders Drug Market Size Forecast (2021-2026)
12.6.1 Middle East and Africa: Genetic Disorders Drug Sales Forecast (2021-2026)
12.6.2 Middle East and Africa: Genetic Disorders Drug Revenue Forecast (2021-2026)
12.6.3 Middle East and Africa: Genetic Disorders Drug Market Size Forecast by Country (2021-2026)
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter’s Five Forces Analysis
13.5 Primary Interviews with Key Genetic Disorders Drug Players (Opinion Leaders)
14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Genetic Disorders Drug Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer
Table 1. Genetic Disorders Drug Market Segments
Table 2. Ranking of Global Top Genetic Disorders Drug Manufacturers by Revenue (US$ Million) in 2019
Table 3. Global Genetic Disorders Drug Market Size Growth Rate by Type 2020-2026 (K Doses) & (US$ Million)
Table 4. Major Manufacturers of Cystic Fibrosis (CF)
Table 5. Major Manufacturers of Duchenne Muscular Dystrophy (DMD)
Table 6. Major Manufacturers of Lysosomal Storage Disease (LSD)
Table 7. Major Manufacturers of Paroxysmal Nocturnal Hemoglobinuria (PNH)
Table 8. Global Genetic Disorders Drug Market Size Growth Rate by Application 2020-2026 (K Doses)
Table 9. Global Genetic Disorders Drug Market Size by Region (K Doses) & (US$ Million): 2020 VS 2026
Table 10. Global Genetic Disorders Drug Sales by Regions 2015-2020 (K Doses)
Table 11. Global Genetic Disorders Drug Sales Market Share by Regions (2015-2020)
Table 12. Global Genetic Disorders Drug Revenue by Regions 2015-2020 (US$ Million)
Table 13. Global Genetic Disorders Drug Sales by Manufacturers (2015-2020) (K Doses)
Table 14. Global Genetic Disorders Drug Sales Share by Manufacturers (2015-2020)
Table 15. Global Genetic Disorders Drug Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020)
Table 16. Global Genetic Disorders Drug by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Genetic Disorders Drug as of 2019)
Table 17. Genetic Disorders Drug Revenue by Manufacturers (2015-2020) (US$ Million)
Table 18. Genetic Disorders Drug Revenue Share by Manufacturers (2015-2020)
Table 19. Key Manufacturers Genetic Disorders Drug Price (2015-2020) (USD/Dose)
Table 20. Genetic Disorders Drug Manufacturers Manufacturing Base Distribution and Headquarters
Table 21. Manufacturers Genetic Disorders Drug Product Type
Table 22. Date of International Manufacturers Enter into Genetic Disorders Drug Market
Table 23. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 24. Global Genetic Disorders Drug Sales by Type (2015-2020) (K Doses)
Table 25. Global Genetic Disorders Drug Sales Share by Type (2015-2020)
Table 26. Global Genetic Disorders Drug Revenue by Type (2015-2020) (US$ Million)
Table 27. Global Genetic Disorders Drug Revenue Share by Type (2015-2020)
Table 28. Genetic Disorders Drug Average Selling Price (ASP) by Type 2015-2020 (USD/Dose)
Table 29. Global Genetic Disorders Drug Sales by Application (2015-2020) (K Doses)
Table 30. Global Genetic Disorders Drug Sales Share by Application (2015-2020)
Table 31. North America Genetic Disorders Drug Sales by Country (2015-2020) (K Doses)
Table 32. North America Genetic Disorders Drug Sales Market Share by Country (2015-2020)
Table 33. North America Genetic Disorders Drug Revenue by Country (2015-2020) (US$ Million)
Table 34. North America Genetic Disorders Drug Revenue Market Share by Country (2015-2020)
Table 35. North America Genetic Disorders Drug Sales by Type (2015-2020) (K Doses)
Table 36. North America Genetic Disorders Drug Sales Market Share by Type (2015-2020)
Table 37. North America Genetic Disorders Drug Sales by Application (2015-2020) (K Doses)
Table 38. North America Genetic Disorders Drug Sales Market Share by Application (2015-2020)
Table 39. Europe Genetic Disorders Drug Sales by Country (2015-2020) (K Doses)
Table 40. Europe Genetic Disorders Drug Sales Market Share by Country (2015-2020)
Table 41. Europe Genetic Disorders Drug Revenue by Country (2015-2020) (US$ Million)
Table 42. Europe Genetic Disorders Drug Revenue Market Share by Country (2015-2020)
Table 43. Europe Genetic Disorders Drug Sales by Type (2015-2020) (K Doses)
Table 44. Europe Genetic Disorders Drug Sales Market Share by Type (2015-2020)
Table 45. Europe Genetic Disorders Drug Sales by Application (2015-2020) (K Doses)
Table 46. Europe Genetic Disorders Drug Sales Market Share by Application (2015-2020)
Table 47. Asia Pacific Genetic Disorders Drug Sales by Region (2015-2020) (K Doses)
Table 48. Asia Pacific Genetic Disorders Drug Sales Market Share by Region (2015-2020)
Table 49. Asia Pacific Genetic Disorders Drug Revenue by Region (2015-2020) (US$ Million)
Table 50. Asia Pacific Genetic Disorders Drug Revenue Market Share by Region (2015-2020)
Table 51. Asia Pacific Genetic Disorders Drug Sales by Type (2015-2020) (K Doses)
Table 52. Asia Pacific Genetic Disorders Drug Sales Market Share by Type (2015-2020)
Table 53. Asia Pacific Genetic Disorders Drug Sales by Application (2015-2020) (K Doses)
Table 54. Asia Pacific Genetic Disorders Drug Sales Market Share by Application (2015-2020)
Table 55. Latin America Genetic Disorders Drug Sales by Country (2015-2020) (K Doses)
Table 56. Latin America Genetic Disorders Drug Sales Market Share by Country (2015-2020)
Table 57. Latin Americaa Genetic Disorders Drug Revenue by Country (2015-2020) (US$ Million)
Table 58. Latin America Genetic Disorders Drug Revenue Market Share by Country (2015-2020)
Table 59. Latin America Genetic Disorders Drug Sales by Type (2015-2020) (K Doses)
Table 60. Latin America Genetic Disorders Drug Sales Market Share by Type (2015-2020)
Table 61. Latin America Genetic Disorders Drug Sales by Application (2015-2020) (K Doses)
Table 62. Latin America Genetic Disorders Drug Sales Market Share by Application (2015-2020)
Table 63. Middle East and Africa Genetic Disorders Drug Sales by Country (2015-2020) (K Doses)
Table 64. Middle East and Africa Genetic Disorders Drug Sales Market Share by Country (2015-2020)
Table 65. Middle East and Africa Genetic Disorders Drug Revenue by Country (2015-2020) (US$ Million)
Table 66. Middle East and Africa Genetic Disorders Drug Revenue Market Share by Country (2015-2020)
Table 67. Middle East and Africa Genetic Disorders Drug Sales by Type (2015-2020) (K Doses)
Table 68. Middle East and Africa Genetic Disorders Drug Sales Market Share by Type (2015-2020)
Table 69. Middle East and Africa Genetic Disorders Drug Sales by Application (2015-2020) (K Doses)
Table 70. Middle East and Africa Genetic Disorders Drug Sales Market Share by Application (2015-2020)
Table 71. Sanofi Corporation Information
Table 72. Sanofi Description and Major Businesses
Table 73. Sanofi Genetic Disorders Drug Production (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2015-2020)
Table 74. Sanofi Product
Table 75. Sanofi Recent Development
Table 76. Vertex Corporation Information
Table 77. Vertex Description and Major Businesses
Table 78. Vertex Genetic Disorders Drug Production (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2015-2020)
Table 79. Vertex Product
Table 80. Vertex Recent Development
Table 81. Takeda Corporation Information
Table 82. Takeda Description and Major Businesses
Table 83. Takeda Genetic Disorders Drug Production (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2015-2020)
Table 84. Takeda Product
Table 85. Takeda Recent Development
Table 86. Amgen Corporation Information
Table 87. Amgen Description and Major Businesses
Table 88. Amgen Genetic Disorders Drug Production (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2015-2020)
Table 89. Amgen Product
Table 90. Amgen Recent Development
Table 91. GW Pharmaceuticals Corporation Information
Table 92. GW Pharmaceuticals Description and Major Businesses
Table 93. GW Pharmaceuticals Genetic Disorders Drug Production (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2015-2020)
Table 94. GW Pharmaceuticals Product
Table 95. GW Pharmaceuticals Recent Development
Table 96. Pfizer Corporation Information
Table 97. Pfizer Description and Major Businesses
Table 98. Pfizer Genetic Disorders Drug Production (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2015-2020)
Table 99. Pfizer Product
Table 100. Pfizer Recent Development
Table 101. BioMarin Corporation Information
Table 102. BioMarin Description and Major Businesses
Table 103. BioMarin Genetic Disorders Drug Production (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2015-2020)
Table 104. BioMarin Product
Table 105. BioMarin Recent Development
Table 106. Sarepta Corporation Information
Table 107. Sarepta Description and Major Businesses
Table 108. Sarepta Genetic Disorders Drug Production (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2015-2020)
Table 109. Sarepta Product
Table 110. Sarepta Recent Development
Table 111. Global Genetic Disorders Drug Sales Forecast by Regions (2021-2026) (K Doses)
Table 112. Global Genetic Disorders Drug Sales Market Share Forecast by Regions (2021-2026)
Table 113. Global Genetic Disorders Drug Revenue Forecast by Regions (2021-2026) (US$ Million)
Table 114. Global Genetic Disorders Drug Revenue Market Share Forecast by Regions (2021-2026)
Table 115. North America: Genetic Disorders Drug Sales Forecast by Country (2021-2026) (K Doses)
Table 116. North America: Genetic Disorders Drug Revenue Forecast by Country (2021-2026) (US$ Million)
Table 117. Europe: Genetic Disorders Drug Sales Forecast by Country (2021-2026) (K Doses)
Table 118. Europe: Genetic Disorders Drug Revenue Forecast by Country (2021-2026) (US$ Million)
Table 119. Asia Pacific: Genetic Disorders Drug Sales Forecast by Region (2021-2026) (K Doses)
Table 120. Asia Pacific: Genetic Disorders Drug Revenue Forecast by Region (2021-2026) (US$ Million)
Table 121. Latin America: Genetic Disorders Drug Sales Forecast by Country (2021-2026) (K Doses)
Table 122. Latin America: Genetic Disorders Drug Revenue Forecast by Country (2021-2026) (US$ Million)
Table 123. Middle East and Africa: Genetic Disorders Drug Sales Forecast by Country (2021-2026) (K Doses)
Table 124. Middle East and Africa: Genetic Disorders Drug Revenue Forecast by Country (2021-2026) (US$ Million)
Table 125. Key Opportunities and Drivers: Impact Analysis (2021-2026)
Table 126. Key Challenges
Table 127. Market Risks
Table 128. Main Points Interviewed from Key Genetic Disorders Drug Players
Table 129. Genetic Disorders Drug Customers List
Table 130. Genetic Disorders Drug Distributors List
Table 131. Research Programs/Design for This Report
Table 132. Key Data Information from Secondary Sources
Table 133. Key Data Information from Primary Sources
List of Figures
Figure 1. Genetic Disorders Drug Product Picture
Figure 2. Global Genetic Disorders Drug Sales Market Share by Type in 2020 & 2026
Figure 3. Cystic Fibrosis (CF) Product Picture
Figure 4. Duchenne Muscular Dystrophy (DMD) Product Picture
Figure 5. Lysosomal Storage Disease (LSD) Product Picture
Figure 6. Paroxysmal Nocturnal Hemoglobinuria (PNH) Product Picture
Figure 7. Global Genetic Disorders Drug Sales Market Share by Application in 2020 & 2026
Figure 8. Clinic
Figure 9. Hospital
Figure 10. Genetic Disorders Drug Report Years Considered
Figure 11. Global Genetic Disorders Drug Market Size 2015-2026 (US$ Million)
Figure 12. Global Genetic Disorders Drug Sales 2015-2026 (K Doses)
Figure 13. Global Genetic Disorders Drug Market Size Market Share by Region: 2020 Versus 2026
Figure 14. Global Genetic Disorders Drug Sales Market Share by Region (2015-2020)
Figure 15. Global Genetic Disorders Drug Sales Market Share by Region in 2019
Figure 16. Global Genetic Disorders Drug Revenue Market Share by Region (2015-2020)
Figure 17. Global Genetic Disorders Drug Revenue Market Share by Region in 2019
Figure 18. Global Genetic Disorders Drug Sales Share by Manufacturer in 2019
Figure 19. The Top 10 and 5 Players Market Share by Genetic Disorders Drug Revenue in 2019
Figure 20. Genetic Disorders Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 21. Global Genetic Disorders Drug Sales Market Share by Type (2015-2020)
Figure 22. Global Genetic Disorders Drug Sales Market Share by Type in 2019
Figure 23. Global Genetic Disorders Drug Revenue Market Share by Type (2015-2020)
Figure 24. Global Genetic Disorders Drug Revenue Market Share by Type in 2019
Figure 25. Global Genetic Disorders Drug Market Share by Price Range (2015-2020)
Figure 26. Global Genetic Disorders Drug Sales Market Share by Application (2015-2020)
Figure 27. Global Genetic Disorders Drug Sales Market Share by Application in 2019
Figure 28. Global Genetic Disorders Drug Revenue Market Share by Application (2015-2020)
Figure 29. Global Genetic Disorders Drug Revenue Market Share by Application in 2019
Figure 30. North America Genetic Disorders Drug Sales Growth Rate 2015-2020 (K Doses)
Figure 31. North America Genetic Disorders Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 32. North America Genetic Disorders Drug Sales Market Share by Country in 2019
Figure 33. North America Genetic Disorders Drug Revenue Market Share by Country in 2019
Figure 34. U.S. Genetic Disorders Drug Sales Growth Rate (2015-2020) (K Doses)
Figure 35. U.S. Genetic Disorders Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 36. Canada Genetic Disorders Drug Sales Growth Rate (2015-2020) (K Doses)
Figure 37. Canada Genetic Disorders Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 38. North America Genetic Disorders Drug Market Share by Type in 2019
Figure 39. North America Genetic Disorders Drug Market Share by Application in 2019
Figure 40. Europe Genetic Disorders Drug Sales Growth Rate 2015-2020 (K Doses)
Figure 41. Europe Genetic Disorders Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 42. Europe Genetic Disorders Drug Sales Market Share by Country in 2019
Figure 43. Europe Genetic Disorders Drug Revenue Market Share by Country in 2019
Figure 44. Germany Genetic Disorders Drug Sales Growth Rate (2015-2020) (K Doses)
Figure 45. Germany Genetic Disorders Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 46. France Genetic Disorders Drug Sales Growth Rate (2015-2020) (K Doses)
Figure 47. France Genetic Disorders Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 48. U.K. Genetic Disorders Drug Sales Growth Rate (2015-2020) (K Doses)
Figure 49. U.K. Genetic Disorders Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 50. Italy Genetic Disorders Drug Sales Growth Rate (2015-2020) (K Doses)
Figure 51. Italy Genetic Disorders Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 52. Russia Genetic Disorders Drug Sales Growth Rate (2015-2020) (K Doses)
Figure 53. Russia Genetic Disorders Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 54. Europe Genetic Disorders Drug Market Share by Type in 2019
Figure 55. Europe Genetic Disorders Drug Market Share by Application in 2019
Figure 56. Asia Pacific Genetic Disorders Drug Sales Growth Rate 2015-2020 (K Doses)
Figure 57. Asia Pacific Genetic Disorders Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 58. Asia Pacific Genetic Disorders Drug Sales Market Share by Region in 2019
Figure 59. Asia Pacific Genetic Disorders Drug Revenue Market Share by Region in 2019
Figure 60. China Genetic Disorders Drug Sales Growth Rate (2015-2020) (K Doses)
Figure 61. China Genetic Disorders Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 62. Japan Genetic Disorders Drug Sales Growth Rate (2015-2020) (K Doses)
Figure 63. Japan Genetic Disorders Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 64. South Korea Genetic Disorders Drug Sales Growth Rate (2015-2020) (K Doses)
Figure 65. South Korea Genetic Disorders Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 66. India Genetic Disorders Drug Sales Growth Rate (2015-2020) (K Doses)
Figure 67. India Genetic Disorders Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 68. Australia Genetic Disorders Drug Sales Growth Rate (2015-2020) (K Doses)
Figure 69. Australia Genetic Disorders Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 70. Taiwan Genetic Disorders Drug Sales Growth Rate (2015-2020) (K Doses)
Figure 71. Taiwan Genetic Disorders Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 72. Indonesia Genetic Disorders Drug Sales Growth Rate (2015-2020) (K Doses)
Figure 73. Indonesia Genetic Disorders Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 74. Thailand Genetic Disorders Drug Sales Growth Rate (2015-2020) (K Doses)
Figure 75. Thailand Genetic Disorders Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 76. Malaysia Genetic Disorders Drug Sales Growth Rate (2015-2020) (K Doses)
Figure 77. Malaysia Genetic Disorders Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 78. Philippines Genetic Disorders Drug Sales Growth Rate (2015-2020) (K Doses)
Figure 79. Philippines Genetic Disorders Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 80. Vietnam Genetic Disorders Drug Sales Growth Rate (2015-2020) (K Doses)
Figure 81. Vietnam Genetic Disorders Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 82. Asia Pacific Genetic Disorders Drug Market Share by Type in 2019
Figure 83. Asia Pacific Genetic Disorders Drug Market Share by Application in 2019
Figure 84. Latin America Genetic Disorders Drug Sales Growth Rate 2015-2020 (K Doses)
Figure 85. Latin America Genetic Disorders Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 86. Latin America Genetic Disorders Drug Sales Market Share by Country in 2019
Figure 87. Latin America Genetic Disorders Drug Revenue Market Share by Country in 2019
Figure 88. Mexico Genetic Disorders Drug Sales Growth Rate (2015-2020) (K Doses)
Figure 89. Mexico Genetic Disorders Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 90. Brazil Genetic Disorders Drug Sales Growth Rate (2015-2020) (K Doses)
Figure 91. Brazil Genetic Disorders Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 92. Argentina Genetic Disorders Drug Sales Growth Rate (2015-2020) (K Doses)
Figure 93. Argentina Genetic Disorders Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 94. Latin America Genetic Disorders Drug Market Share by Type in 2019
Figure 95. Latin America Genetic Disorders Drug Market Share by Application in 2019
Figure 96. Middle East and Africa Genetic Disorders Drug Sales Growth Rate 2015-2020 (K Doses)
Figure 97. Middle East and Africa Genetic Disorders Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 98. Middle East and Africa Genetic Disorders Drug Sales Market Share by Country in 2019
Figure 99. Middle East and Africa Genetic Disorders Drug Revenue Market Share by Country in 2019
Figure 100. Turkey Genetic Disorders Drug Sales Growth Rate (2015-2020) (K Doses)
Figure 101. Turkey Genetic Disorders Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 102. Saudi Arabia Genetic Disorders Drug Sales Growth Rate (2015-2020) (K Doses)
Figure 103. Saudi Arabia Genetic Disorders Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 104. U.A.E Genetic Disorders Drug Sales Growth Rate (2015-2020) (K Doses)
Figure 105. U.A.E Genetic Disorders Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 106. Middle East and Africa Genetic Disorders Drug Market Share by Type in 2019
Figure 107. Middle East and Africa Genetic Disorders Drug Market Share by Application in 2019
Figure 108. North America Genetic Disorders Drug Sales Growth Rate Forecast (2021-2026) (K Doses)
Figure 109. North America Genetic Disorders Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 110. Europe Genetic Disorders Drug Sales Growth Rate Forecast (2021-2026) (K Doses)
Figure 111. Europe Genetic Disorders Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 112. Asia Pacific Genetic Disorders Drug Sales Growth Rate Forecast (2021-2026) (K Doses)
Figure 113. Asia Pacific Genetic Disorders Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 114. Latin America Genetic Disorders Drug Sales Growth Rate Forecast (2021-2026) (K Doses)
Figure 115. Latin America Genetic Disorders Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 116. Middle East and Africa Genetic Disorders Drug Sales Growth Rate Forecast (2021-2026) (K Doses)
Figure 117. Middle East and Africa Genetic Disorders Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 118. Porter's Five Forces Analysis
Figure 119. Channels of Distribution
Figure 120. Distributors Profiles
Figure 121. Bottom-up and Top-down Approaches for This Report
Figure 122. Data Triangulation
Figure 123. Key Executives Interviewed
遺伝子解析サービスの世界市場（～2026年） Genetic analysis refers to study of DNA and RNA or the basic structure of genes for varied analytical purposes Genetic analysis has emerged as an important tool in the fields of diagnostics, drug discovery, and biomedical research. It is helpful in determining occurrence of diseases and errors in me…- 遺伝病診断の世界市場（～2026年） Test the genetic disease. For example, color blindness, Down'ssyndrome, cystic fibrosis,etc Rising incidences of genetic disorders that give rise to wide variety of independent diagnostic procedures globally is predominantly driving the growth of the global genetic disorder diagnostic market. Additi…
- ベッカー型筋ジストロフィー治療薬の世界市場（～2026年） Market Analysis and Insights: Global Becker Muscular Dystrophy Drug Market The global Becker Muscular Dystrophy Drug market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Becker Muscular Dystrophy Drug Scope and Market Size …
- パニック障害の世界市場（～2026年） Panic disorder is an anxiety disorder characterized by reoccurring unexpected panic attacks. Panic disorder is usually treated with counselling and medications. The type of counselling used is typically cognitive behavioral therapy which is effective in more than half of people. Medications used inc…
- 遺伝子検査の世界市場（～2026年） Genetic testing, also known as DNA testing, allows the determination of bloodlines and the genetic diagnosis of vulnerabilities to inherited diseases. In agriculture, a form of genetic testing known as progeny testing can be used to evaluate the quality of breeding stock. In population ecology, gene…